PPT-Median PFS: 2.6 months (95% CI, 1.7-3.5)

Median PFS 14 months 95 CI 1216 Median PFS 12 months 95 CI 047 A B C Cancer Prior to TAS117 n13 TAS117 n13 Subsequent line of treatment n6 Breast cancer 3. Oncology. Hemangiosarcoma. Bone Sarcomas. Wendy Blount, . DVM. Hemangiosarcoma. Diagnosis. Many oncologists condone fine needle aspiration of abdominal masses. Doing so increases risk of hemorrhage. I prefer diagnostic surgery with splenectomy if no evidence of metastasis. Yes . Deborah . Schrag. , MD, MPH. No. John L. Marshall, MD. Maintenance. Why we do it. Optimox. , should we . optimiri. Timing of change. Switch or reduce. What drugs. 5fu or . capecitabine. Bev? . Erlotinib. Oh My!. Nathan L. Abbott, . CFE. , . CISA. , . EA. OBJECTIVE. To provide an overview of fraud cases that have occurred in Tennessee and the Tools we developed to help prevent them and Data.. “Never trust the people you cheat with. They will throw you under the bus.” . Oncology. Hemangiosarcoma. Bone Sarcomas. Wendy Blount, . DVM. Hemangiosarcoma. Diagnosis. Many oncologists condone fine needle aspiration of abdominal masses. Aspiration of peripheral masses often yields blood only. prioritise . TB investigation among HIV+ adults in . South . Africa. Xpert MTB/RIF for people attending HIV care: an interventional cohort study to guide rational implementation (XPHACTOR). Alison Grant. . Vedotin. Should be the Second Line Regimen of Choice for Recurrent Hodgkin Lymphoma Prior to Stem Cell Transplant. Catherine Diefenbach, MD. Assistant Professor of Medicine. NYU . Perlmutter. Cancer Center, NYU . 10/25/2016. Objectives. General principles. Endocrine agents for HR+ pts- . sequencing/combinations. Addition of biological agents. Clinical scenarios. Triple negative subsets. AR positive disease. PARP inhibitors in BRCA mutations. therapies . for . cholangiocarcinoma. Professor Juan . W Valle. Professor & Honorary Consultant in Medical Oncology. The Christie NHS Foundation . Trust . University of . Manchester. 11. th. May 2017. Sipuleucel. -T was approved based on HR of 0.775 . (~4-month OS benefit). Survival curves separated after 6 months. Significant PSA decline rate ~3%. No improvement in time to progression. Very few side effects. Simon Rule. Professor of Clinical . Haematology. Consultant . Haematologist. Derriford. Hospital and Peninsula Medical School Plymouth. DISCLOSURES OF COMMERCIAL SUPPORT. Name of Company. Research support. Stanford University. Outline. Abstract #4. :. . Intermittent (IAD) versus continuous androgen deprivation (CAD) . in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. . actual. . video-recorded proceedings from the . live . CME event and may include the use of trade names and other raw, unedited content. . Emerging role of immune checkpoint inhibitors and other novel strategies in MPM. Lisocabtagene. . Maraleucel. in Relapsed/Refractory (R/R) Large B-Cell Lymphomas . Abramson JS, . Palomba. ML, Gordon LI, . Lunning. M, Wang M, . Arnason. J, Mehta A, . Purev. E, Maloney DG, . Andreadis. Charleston, SC. Bones, Hot Flashes, and ADT Use With Chemotherapy and Timing. Toxicities of ADT. Hot Flashes, sexual dysfunction and many other complications of therapy are seen in greater than 90% of men on ADT.